Document:

exv10w22

 

Exhibit 10.22

EXECUTION COPY

ADNEXUS THERAPEUTICS, INC.

SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

     This Second Amended and Restated Investor Rights Agreement (this “Agreement”) dated as of July
11, 2007 is entered into by and among Adnexus Therapeutics, Inc., a Delaware corporation (the
“Company”), the Purchasers (as defined below), the Common Stockholders (as defined below), General
Electric Capital Corporation (“GE’) and Comerica Bank (“Comerica”).

Recitals

     WHEREAS, the Series A Purchasers (as defined below) acquired an aggregate of 57,592,003 shares
of Series A Convertible Preferred Stock of the Company (“Series A Preferred”) pursuant to the terms
of a Series A Convertible Preferred Stock Purchase Agreement dated as of March 31, 2003, as amended
December 15, 2004, by and among the Company and the parties named therein (the “Series A
Purchasers”);

     WHEREAS, the Series B Purchasers (as defined below) acquired an aggregate of 336,952,459
shares of Series B Convertible Preferred Stock of the Company (“Series B Preferred”) pursuant to
the terms of a Series B Convertible Preferred Stock Purchase Agreement dated as of May 10, 2006, by
and among the Company and the parties named therein (the “Series B Purchasers”);

     WHEREAS, the Series C Purchasers (as defined below) are acquiring an aggregate of up to
77,500,000 shares of Series C Convertible Preferred Stock of the Company (“Series C Preferred”)
pursuant to the terms of a Series C Convertible Preferred Stock Purchase Agreement dated as of July
11, 2007 (the “Purchase Agreement”), by and among the Company and the Series C Purchasers;

     WHEREAS, on December 16, 2003, the Company issued to GE 1,600,000 shares of Series A
Preferred;

     WHEREAS, on December 16, 2003, the Company entered into a Loan and Security Agreement with
Comerica, pursuant to which the Company issued a warrant (the “Warrant”) for the purchase of up to
133,334 shares of Series A Preferred;

     WHEREAS, the Company, the Series A Purchasers, the Series B Purchasers, the Common
Stockholders, GE and Comerica are parties to an Amended and Restated Investor Rights Agreement,
dated as of June 14, 2006 (the “Old Investor Rights Agreement”); and

     WHEREAS, the Company and the Purchasers desire to provide for certain arrangements with
respect to (i) the registration of shares of capital stock of the Company under the Securities Act
(as defined below), (ii) the Purchasers’ right of first refusal with respect to certain issuances
of securities of the Company, and (iii) certain covenants of the Company.

 

 

     NOW, THEREFORE, in consideration of the mutual promises and covenants contained in this
Agreement, the parties hereto agree as follows:

     1. Certain Definitions.

     As used in this Agreement, the following terms shall have the following respective meanings:

          “Accredited Investor” shall mean an “accredited investor” within the meaning of Rule
501(a) under the Securities Act.

          “Affiliated Party” means with respect to any Purchaser, any person or entity which,
directly or indirectly, controls, is controlled by or is under common control with such Purchaser,
including, without limitation, any general partner, officer or director of such Purchaser and any
venture capital fund now or hereafter existing which is controlled by one or more general partners
of, or shares the same management company as, such Purchaser.

          “Atlas Entities” means Atlas Venture Fund V, L.P., Atlas Venture Parallel Fund V-A,
Atlas Venture Entrepreneurs’ Fund V, L.P., Atlas Venture Fund VI, L.P., Atlas Venture
Entrepreneurs’ Fund VI, L.P., Atlas Venture Fund VI GmbH & Co. KG and any Affiliated Party of any
of the foregoing.

          “Available Undersubscription Amount” means the difference between the total of all of
the Basic Amounts available for purchase by Qualified Purchasers pursuant to Section 3.1 and the
Basic Amounts subscribed for pursuant to Section 3.1.

          “Basic Amount” means, with respect to a Qualified Purchaser, its pro rata portion of
the Offered Securities determined by multiplying the number of Offered Securities by a fraction,
the numerator of which is the aggregate number of shares of Common Stock then held by such
Qualified Purchaser (assuming the conversion into Common Stock of all shares of convertible
preferred stock then held by such Qualified Purchaser) immediately prior to the issuance of such
Offered Securities and the denominator of which is the total number of shares of Common Stock
outstanding (assuming the conversion into Common Stock of all outstanding shares of convertible
preferred stock) immediately prior to the issuance of such Offered Securities.

          “Code” means the Internal Revenue Code of 1986, as amended.

          “Commission” means the Securities and Exchange Commission, or any other federal agency
at the time administering the Securities Act.

          “Common Stock” means the common stock, $.001 par value per share, of the Company.

          “Common Stockholders” means certain individuals listed on Exhibit B attached
hereto.

- 2 -

 

          “Common Stockholders’ Shares” means the shares of Common Stock held by Common
Stockholders.

          “Company” has the meaning ascribed to it in the introductory paragraph hereto.

          “Company Sale” means: (a) a merger or consolidation in which (i) the Company is a
constituent party, or (ii) a Company Subsidiary is a constituent party and the Company issues
shares of its capital stock pursuant to such merger or consolidation, except in each case any such
merger or consolidation involving the Company or a Company Subsidiary in which the holders of
capital stock of the Company immediately prior to such merger or consolidation continue to hold
immediately following such merger or consolidation in substantially the same proportions at least
51% by voting power of the capital stock of or ownership interest in (A) the surviving or resulting
entity or (B) if the surviving or resulting entity is a wholly owned subsidiary of another entity
immediately following such merger or consolidation, the parent entity of such surviving or
resulting entity; or (b) the sale or disposition, in a single transaction or series of related
transactions, by the Company of all or substantially all the assets of the Company (except where
such sale is to a wholly owned subsidiary of the Company).

          “Company Subsidiary” means any corporation, partnership, trust, limited liability
company or other non-corporate business enterprise in which the Company (or another Company
Subsidiary) holds stock or other ownership interests representing (a) more that 50% of the voting
power of all outstanding stock or ownership interests of such entity or (b) the right to receive
more than 50% of the net assets of such entity available for distribution to the holders of
outstanding stock or ownership interests upon a liquidation or dissolution of such entity.

          “Confidential Information” means any information that is labeled as confidential,
proprietary or secret which a Purchaser obtains from the Company pursuant to financial statements,
reports and other materials provided by the Company to such Purchaser pursuant to this Agreement or
pursuant to visitation or inspection rights granted hereunder.

          “Exchange Act” means the Securities Exchange Act of 1934, as amended, or any successor
federal statute, and the rules and regulations of the Commission issued under such Act, as they
each may, from time to time, be in effect.

          “Flagship Entities” means Applied Genomic Technology Capital Fund, L.P., AGTC Advisors
Fund, L.P., NewcoGen Group LLC, NewcoGen Equity Investors LLC, NewcoGen PE LLC, NewcoGen Elan LLC,
ST NewcoGen LLC, NewcoGen Long Reign Holding LLC and any Affiliated Party of any of the foregoing.

          “HBM Entity” means HBM BioVentures (Cayman) Ltd.

          “Indemnified Party” means a party entitled to indemnification pursuant to Section 2.5.

          “Indemnifying Party” means a party obligated to provide indemnification pursuant to
Section 2.5.

- 3 -

 

          “Initiating Holders” means the Purchasers initiating a request for registration
pursuant to Section 2.1(a) or 2.1(b), as the case may be.

          “Initial Public Offering” means the initial underwritten public offering of shares of
Common Stock pursuant to an effective Registration Statement.

          “Investor Director” means a member of the Board of Directors designated solely by any
of the Flagship Entities, the Polaris Entities, the Atlas Entities, the Venrock Entities or the HBM
Entity pursuant to that certain Second Amended and Restated Stockholders’ Voting Agreement, dated
as of the date hereof.

          “Notice of Acceptance” means a written notice from a Purchaser to the Company
containing the information specified in Section 3.1(b).

          “Offer” means a written notice of any proposed or intended issuance, sale or exchange
of Offered Securities containing the information specified in Section 3.1(a).

          “Offered Securities” means (i) any shares of Common Stock, (ii) any other equity
securities of the Company, including, without limitation, shares of preferred stock, (iii) any
option, warrant or other right to subscribe for, purchase or otherwise acquire any equity
securities of the Company, or (iv) any debt securities convertible into capital stock of the
Company.

          “Other Holders” means holders of securities of the Company (other than Purchasers) who
are entitled, by contract with the Company, to have securities included in a Registration
Statement.

          “Polaris Entities” means Polaris Venture Partners IV, L.P., Polaris Venture Partners
Entrepreneurs’ Fund IV, L.P. and any Affiliated Party of any of the foregoing.

          “Prospectus” means the prospectus included in any Registration Statement, as amended
or supplemented by an amendment or prospectus supplement, including post-effective amendments, and
all material incorporated by reference or deemed to be incorporated by reference in such
Prospectus.

          “Purchase Agreement” has the meaning ascribed to it in the recitals hereto.

          “Purchasers” means the Series A Purchasers, the Series B Purchasers, the Series C
Purchasers and GE.

          “Qualified Public Offering” shall mean a public offering of shares of Common Stock
pursuant to an effective Registration Statement at a price to the public of at least $.35 per share
and resulting in at least $40,000,000 of gross proceeds to the Company.

          “Qualified Purchaser” means a Significant Holder that is an Accredited Investor.

- 4 -

 

          “Refused Securities” means those Offered Securities as to which a Notice of Acceptance
has not been given by the Qualified Purchasers pursuant to Section 3.1.

          “Registrable Shares” means (a) the Common Stockholders’ Shares, (b) the shares of
Common Stock issued or issuable upon conversion of the Shares, (c) the shares of Common Stock
issued or issuable upon exercise of that certain warrant to purchase shares of Common Stock issued
to GE on September 25, 2003, (d) the shares of Common Stock issued or issuable upon exercise of
that certain warrant or warrants issued to Comerica pursuant to that certain Loan and Security
Agreement dated as of December 16, 2003, (e) any other shares of Common Stock, and any shares of
Common Stock issued or issuable upon the conversion or exercise of any other securities acquired by
the Purchasers pursuant to Section 3 of this Agreement or pursuant to the Second Amended and
Restated Right of First Refusal and Co-Sale Agreement among the Company, the Purchasers and certain
other parties thereto dated as of the date hereof and (f) any other shares of Common Stock issued
in respect of such shares (because of stock splits, stock dividends, reclassifications,
recapitalizations or similar events); provided, however, that shares of Common Stock which are
Registrable Shares shall cease to be Registrable Shares (i) upon any sale pursuant to a
Registration Statement or Rule 144 under the Securities Act or (ii) upon any sale in any manner to
a person or entity which is not entitled, pursuant to Section 6, to the rights under this Agreement
or (iii) with respect solely to the Common Stockholders’ Shares, at such time, following an Initial
Public Offering, as they become eligible for sale pursuant to Rule 144(k) under the Securities Act.
Wherever reference is made in this Agreement to a request or consent of holders of a certain
percentage of Registrable Shares, the determination of such percentage shall include shares of
Common Stock issuable upon conversion of the Shares even if such conversion has not been effected.

          “Registration Expenses” means all expenses incurred by the Company in complying with
the provisions of Section 2, including, without limitation, all registration and filing fees,
exchange listing fees, printing expenses, fees and expenses of counsel for the Company and the fees
and expenses of one counsel selected by the Selling Stockholders holding a majority of the
Registrable Shares to be sold in such offering to represent the Selling Stockholders, state Blue
Sky fees and expenses, and the expense of any special audits incident to or required by any such
registration, but excluding underwriting discounts, selling commissions and the fees and expenses
of Selling Stockholders’ own counsel (other than the counsel selected to represent all Selling
Stockholders).

          “Registration Statement” means a registration statement filed by the Company with the
Commission for a public offering and sale of securities of the Company (other than a registration
statement on Form S-8 or Form S-4, or their successors, or any other form for a similar limited
purpose, or any registration statement covering only securities proposed to be issued in exchange
for securities or assets of another corporation).

          “Securities Act” means the Securities Act of 1933, as amended, or any successor
federal statute, and the rules and regulations of the Commission issued under such Act, as they
each may, from time to time, be in effect.

- 5 -

 

          “Selling Stockholder” means any Stockholder owning Registrable Shares included in a
Registration Statement.

          “Series A Purchasers” has the meaning ascribed to it in the introductory paragraph
hereto and shall include all Affiliates of a Purchaser who hold shares of Series A Preferred Stock.

          “Series B Purchaser” has the meaning ascribed to it in the introductory paragraph
hereto and shall include all Affiliates of a Purchaser who hold shares of Series B Preferred Stock.

          “Series C Purchaser” means an individual or entity who purchases shares of Series C
Preferred on or prior to the date hereof pursuant to the Purchase Agreement.

          “Shares” means (i) Series A Preferred issued to the Series A Purchasers, (ii) Series B
Preferred issued to the Series B Purchasers and (iii) Series C Preferred issued to the Series C
Purchasers pursuant to the terms of the Purchase Agreement; provided, however, that for purposes of
exercising rights under this Agreement, Shares owned by a Purchaser shall be deemed to include
Shares which have been converted into Common Stock so long as such Common Stock is owned by such
Purchaser.

          “Significant Holder” means a Purchaser who is the record owner of at least 250,000
Shares (subject to appropriate adjustment for stock splits, stock dividends, recapitalizations and
similar events occurring after the date of this Agreement).

          “Special Registration Statement” means a Registration Statement filed pursuant to
Section 2.1, or a Registration Statement on Form S-4, S-8 or another form not available for
registering the Registrable Shares for sale to the public.

          “Stockholders” means (i) the Common Stockholders, the Purchasers and any persons or
entities to whom the rights granted under this Agreement are transferred by a Purchaser or its
successors or assigns pursuant to Section 6.1 hereof and (ii) for purposes of Sections 1, 2, 6 and
7 only, Comerica and GE.

          “Undersubscription Amount” means, with respect to a Qualified Purchaser, any
additional portion of the Offered Securities attributable to the Basic Amounts of other Qualified
Purchasers as such Qualified Purchaser indicates it will purchase or acquire should the other
Qualified Purchasers subscribe for less than their Basic Amounts.

     2. Registration Rights.

          2.1 Required Registrations.

               (a) At any time after six months following the closing of the Initial Public Offering, a
Stockholder or Stockholders (excluding the Common Stockholders) holding in the aggregate at least a
majority of the Registrable Shares held by all such Stockholders (or a lesser percentage if the
total value of the Registrable Shares requested to be registered is at least $7,500,000) may
request, in writing, that the Company effect the registration on Form S-1 or

- 6 -

 

Form S-2 (or any successor form) of Registrable Shares owned by such Stockholder or
Stockholders.

               (b) At any time after the Company becomes eligible to file a Registration Statement on Form
S-3 (or any successor form relating to secondary offerings), a Stockholder or Stockholders
(excluding the Common Stockholders) holding Registrable Shares may request, in writing, that the
Company effect the registration on Form S-3 (or such successor form), of Registrable Shares having
an aggregate offering price of at least $1,000,000 (based on the market price on the date of such
request).

               (c) Upon receipt of any request for registration pursuant to this Section 2, the Company shall
promptly give written notice of such proposed registration to all other Stockholders. Such
Stockholders shall have the right, by giving written notice to the Company within 30 days after the
Company provides its notice, to elect to have included in such registration such of their
Registrable Shares as such Stockholders may request in such notice of election, subject in the case
of an underwritten offering to the terms of Section 2.1(d). Thereupon, the Company shall, as
expeditiously as possible, use its best efforts to effect the registration on an appropriate
registration form of all Registrable Shares which the Company has been requested to so register;
provided, however, that in the case of a registration requested under Section 2.1(b), the Company
will only be obligated to effect such registration on Form S-3 (or any successor form).

               (d) If the Initiating Holders intend to distribute the Registrable Shares covered by their
request by means of an underwriting, they shall so advise the Company as a part of their request
made pursuant to Section 2.1(a) or (b), as the case may be, and the Company shall include such
information in its written notice referred to in Section 2.1(c). In such event, (i) the right of
any other Stockholder to include its Registrable Shares in such registration pursuant to Section
2.1(a) or (b), as the case may be, shall be conditioned upon such other Stockholder’s participation
in such underwriting on the terms thereof, and (ii) all Stockholders including Registrable Shares
in such registration shall enter into an underwriting agreement upon customary terms with the
underwriter or underwriters managing the offering. If any Stockholder who has requested inclusion
of its Registrable Shares in such registration as provided above disapproves of the terms of the
underwriting, such person may elect, by written notice to the Company, to withdraw its Registrable
Shares from such Registration Statement and underwriting. If the Company desires that any officers
or directors of the Company holding securities of the Company be included in any registration for
an underwritten offering requested pursuant to Section 2.1 or if Other Holders request such
inclusion, the Company may include the securities of such officers, directors and Other Holders in
such registration and underwriting on the terms thereof applicable to the Stockholders. If the
managing underwriter advises the Company in writing that marketing factors require a limitation on
the number of shares to be underwritten, the shares held by officers or directors of the Company,
Other Holders and Common Stockholders shall be first excluded from such Registration Statement and
underwriting to the extent deemed advisable by the managing underwriter, and if a further reduction
of the number of shares is required after all such shares have been excluded, the number of shares
that may be included in such Registration Statement and underwriting shall be allocated among all
Purchasers requesting registration in proportion, as nearly as practicable, to

- 7 -

 

the respective number of Registrable Shares held by them on the date of the request for
registration made by the Initiating Holders pursuant to Section 2.1(a) or (b), as the case may be.
If any such stockholder would thus be entitled to include more shares than such stockholder
requested to be registered, the excess shall be allocated among other participating stockholders
pro rata in the manner described in the preceding sentence. If the managing underwriter has not
limited the number of Registrable Shares or other securities to be underwritten, the Company may
include securities for its own account in such registration if the managing underwriter so agrees
and if the number of Registrable Shares and other securities which would otherwise have been
included in such registration and underwriting will not thereby be limited.

               (e) The Company shall not be required to effect more than two registrations pursuant to
Section 2.1(a), or more than two registrations per year pursuant to Section 2.1(b). For purposes of
this Section 2.1(e), a Registration Statement shall not be counted for purposes of this Section
2.1(e) until such time as such Registration Statement has been declared effective by the Commission
and at least 25% of the Registrable Shares requested to be included shall have been sold (unless
the Initiating Holders withdraw their request for such registration (other than as a result of
information concerning the business or financial condition of the Company which is made known to
the Stockholders after the date on which such registration was requested) and elect not to pay the
Registration Expenses therefor pursuant to Section 2.4).

               (f) If at the time of any request to register Registrable Shares by Initiating Holders
pursuant to this Section 2.1, the Company is engaged or has fixed plans to engage within 30 days of
the request in a registered public offering as to which the Initiating Holders may include
Registrable Shares pursuant to Section 2.2. or is engaged in any other activity which, in the good
faith determination of the Company’s Board of Directors, would be materially adversely affected by
the requested registration, then the Company may at its option direct that such request be delayed
for a period not in excess of 90 days from the date of such request, such right to delay a request
to be exercised by the Company not more than once in any 24-month period.

               (g) The Company will not file with the Commission any other registration statement with
respect to its Common Stock other than a Special Registration Statement, whether for its own
account or that of Other Holders, from the date of receipt of a notice from requesting holders
pursuant to this Section 2.1 until the completion of the period of distribution of the registration
contemplated thereby.

          2.2 Incidental Registration.

               (a) Whenever the Company proposes to file a Registration Statement covering shares of Common
Stock (other than a Special Registration Statement) at any time and from time to time, it will,
prior to such filing, give written notice to all Stockholders of its intention to do so; provided,
that no such notice need be given if no Registrable Shares are to be included therein as a result
of a written notice from the managing underwriter pursuant to Section 2.2(b). Upon the written
request of any Stockholder given within 20 days after the Company provides such notice (which
request shall state the intended method of disposition of

- 8 -

 

such Registrable Shares), the Company shall use its best efforts to cause all Registrable
Shares which the Company has been requested by such Stockholder to register to be registered under
the Securities Act to the extent necessary to permit their sale or other disposition in accordance
with the intended methods of distribution specified in the request of such Stockholder; provided
that the Company shall have the right to postpone or withdraw any registration effected pursuant to
this Section 2.2 without obligation to any Stockholder.

               (b) If the registration for which the Company gives notice pursuant to Section 2.2(a) is a
registered public offering involving an underwriting, the Company shall so advise the Stockholders
as a part of the written notice given pursuant to Section 2.2(a). In such event, (i) the right of
any Stockholder to include its Registrable Shares in such registration pursuant to this Section 2.2
shall be conditioned upon such Stockholder’s participation in such underwriting on the terms
thereof and (ii) all Stockholders including Registrable Shares in such registration shall enter
into an underwriting agreement upon customary terms with the underwriter or underwriters selected
for the underwriting by the Board of Directors of the Company. If any Stockholder who has
requested inclusion of its Registrable Shares in such registration as provided above disapproves of
the terms of the underwriting, such person may elect, by written notice to the Company, to withdraw
its shares from such Registration Statement and underwriting. If the managing underwriter advises
the Company in writing that marketing factors require a limitation on the number of shares to be
underwritten, the Company and its underwriters shall allocate the number of Registrable Shares
requested to be registered by each of the holders thereof as follows: (i) first, to the Company;
(ii) second, to the Purchasers who have elected to participate in such offering, pro rata according
to the number of Registrable Shares held by each such Purchaser; (iii) third, to the Common
Stockholders who have elected to participate in such offering, pro rata according to the number of
Registrable Shares held by each such Common Stockholder, (iv) fourth, to the other holders of
Registrable Shares (other than the Purchasers and Common Stockholders) who have elected to
participate in such offering, pro rata according to the number of Registrable Shares held by each
such holder; and (v) thereafter, to the extent additional securities may be included in such
offering, to any other holders of Company securities other than Registrable Shares; provided,
however, that no such reduction shall reduce the amount of securities of the Purchasers included in
the registration below thirty percent (30%) of the total amount of securities included in such
registration, unless such offering is the Initial Public Offering and such registration does not
include shares of any other selling stockholders, in which event any or all of the Registrable
Shares of the Purchasers may be excluded in accordance with the immediately preceding clause. If
any Stockholder or Other Holder would thus be entitled to include more shares than such holder
requested to be registered, the excess shall be allocated among other requesting Stockholders and
Other Holders pro rata in the manner described in the preceding sentence.

          2.3 Registration Procedures.

               (a) If and whenever the Company is required by the provisions of this Agreement to use its
best efforts to effect the registration of any Registrable Shares under the Securities Act, the
Company shall:

- 9 -

 

                    (i) as expeditiously as possible prepare and file with the Commission a Registration Statement
with respect to such Registrable Shares and use its best efforts to cause that Registration
Statement to become effective as soon as possible and remain effective in accordance with paragraph
(ii) below;

                    (ii) as expeditiously as possible prepare and file with the Commission any amendments and
supplements to the Registration Statement and the prospectus included in the Registration Statement
as may be necessary to comply with the provisions of the Securities Act (including the anti-fraud
provisions thereof) and to keep the Registration Statement effective for 12 months from the
effective date or such lesser period until all such Registrable Shares are sold (or, in the case of
a firm commitment underwritten offering, until each underwriter has completed the distribution of
all securities purchase by it);

                    (iii) as expeditiously as possible furnish to each Selling Stockholder such reasonable numbers
of copies of the Prospectus, including any preliminary Prospectus, in conformity with the
requirements of the Securities Act, and such other documents as such Selling Stockholder may
reasonably request in order to facilitate the public sale or other disposition of the Registrable
Shares owned by such Selling Stockholder;

                    (iv) as expeditiously as possible use its best efforts to register or qualify the Registrable
Shares covered by the Registration Statement under the securities or Blue Sky laws of such states
as the Selling Stockholders shall reasonably request, and do any and all other acts and things that
may be necessary or desirable to enable the Selling Stockholders to consummate the public sale or
other disposition in such states of the Registrable Shares owned by the Selling Stockholders;
provided, however, that the Company shall not be required in connection with this paragraph (iv) to
qualify as a foreign corporation or execute a general consent to service of process in any
jurisdiction;

                    (v) as expeditiously as possible, cause all such Registrable Shares to be listed on each
securities exchange or automated quotation system on which similar securities issued by the Company
are then listed;

                    (vi) promptly provide a transfer agent and registrar for all such Registrable Shares not later
than the effective date of such registration statement;

                    (vii) promptly make available for inspection by the Selling Stockholders, any managing
underwriter participating in any disposition pursuant to such Registration Statement, and any
attorney or accountant or other agent retained by any such underwriter or selected by the Selling
Stockholders, all financial and other records, pertinent corporate documents and properties of the
Company and cause the Company’s officers, directors, employees and independent accountants to
supply all information reasonably requested by any such seller, underwriter, attorney, accountant
or agent in connection with such Registration Statement;

                    (viii) as expeditiously as possible, notify each Selling Stockholder, promptly after it shall
receive notice thereof, of the time when such Registration

- 10 -

 

Statement has become effective or a supplement to any Prospectus forming a part of such
Registration Statement has been filed;

                    (ix) As expeditiously as possibly, notify each Selling Stockholder of Registrable Shares
covered by such registration statement at any time when a prospectus relating thereto is required
to be delivered under the Securities Act of the happening of any event as a result of which the
prospectus included in such registration statement, as then in effect, includes an untrue statement
of a material fact or omits to state a material fact required to be stated therein or necessary to
make the statements therein not misleading in the light of the circumstances then existing. The
Company will amend or supplement such prospectus in order to cause such prospectus not to include
any untrue statement of a material fact or omit to state a material fact required to be stated
therein or necessary to make the statements therein not misleading in the light of the
circumstances then existing; and

                    (x) as expeditiously as possible following the effectiveness of such Registration Statement,
notify each seller of such Registrable Shares of any request by the Commission for the amending or
supplementing of such Registration Statement or Prospectus or of the issuance of any stop order by
the Commission suspending the effectiveness of such Registration Statement or the initiation or
threatening of any proceeding for such purpose and promptly use all reasonable efforts to prevent
the issuance of any stop or to obtain its withdrawal if such stop order should be issued.

               (b) If the Company has delivered a Prospectus to the Selling Stockholders and after having
done so the Prospectus is amended to comply with the requirements of the Securities Act, the
Company shall promptly notify the Selling Stockholders and, if requested, the Selling Stockholders
shall immediately cease making offers of Registrable Shares and return all Prospectuses to the
Company. The Company shall promptly provide the Selling Stockholders with revised Prospectuses
and, following receipt of the revised Prospectuses, the Selling Stockholders shall be free to
resume making offers of the Registrable Shares.

          2.4 Allocation of Expenses. The Company will pay all Registration Expenses for all
registrations under this Agreement; provided, however, that if a registration under
Section 2.1 is withdrawn at the request of the Initiating Holders (other than as a result of
information concerning the business or financial condition of the Company which is made known to
the Selling Stockholders after the date on which such registration was requested) and if the
Initiating Holders elect not to have such registration counted as a registration requested under
Section 2.1, the Selling Stockholders shall pay the Registration Expenses of such registration pro
rata in accordance with the number of their Registrable Shares included in such registration.

          2.5 Indemnification and Contribution.

               (a) In the event of any registration of any of the Registrable Shares under the Securities Act
pursuant to this Agreement, the Company will indemnify and hold harmless each Selling Stockholder,
each underwriter of such Registrable Shares, and each other person, if any, who controls such
Selling Stockholder or underwriter within the meaning of the

- 11 -

 

Securities Act or the Exchange Act against any losses, claims, damages or liabilities, joint
or several, to which such Selling Stockholder, underwriter or controlling person may become subject
under the Securities Act, the Exchange Act, state securities or Blue Sky laws or otherwise, insofar
as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are
based upon (i) any untrue statement or alleged untrue statement of any material fact contained in
any Registration Statement under which such Registrable Shares were registered under the Securities
Act, any preliminary prospectus or final prospectus contained in the Registration Statement, or any
amendment or supplement to such Registration Statement, (ii) the omission or alleged omission to
state a material fact required to be stated therein or necessary to make the statements therein not
misleading, or (iii) any violation or alleged violation by the Company of the Securities Act, the
Exchange Act, any state securities law or any rule or regulation promulgated under the Securities
Act, the Exchange Act or any state securities law in connection with the Registration Statement or
the offering contemplated thereby; and the Company will reimburse such Selling Stockholder,
underwriter and each such controlling person for any legal or any other expenses reasonably
incurred by such Selling Stockholder, underwriter or controlling person in connection with
investigating or defending any such loss, claim, damage, liability or action; provided,
however, that the Company will not be liable in any such case to the extent that any such
loss, claim, damage or liability arises out of or is based upon any untrue statement or omission
made in such Registration Statement, preliminary prospectus or prospectus, or any such amendment or
supplement, in reliance upon and in conformity with information furnished to the Company, in
writing, by or on behalf of such Selling Stockholder, underwriter or controlling person
specifically for use in the preparation thereof.

               (b) In the event of any registration of any of the Registrable Shares under the Securities Act
pursuant to this Agreement, each Selling Stockholder, severally and not jointly, will indemnify and
hold harmless the Company, each of its directors and officers and each underwriter (if any) and
each person, if any, who controls the Company or any such underwriter within the meaning of the
Securities Act or the Exchange Act, against any losses, claims, damages or liabilities, joint or
several, to which the Company, such directors and officers, underwriter or controlling person may
become subject under the Securities Act, Exchange Act, state securities or Blue Sky laws or
otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof)
arise out of or are based upon (i) any untrue statement or alleged untrue statement of a material
fact contained in any Registration Statement under which such Registrable Shares were registered
under the Securities Act, any preliminary prospectus or final prospectus contained in the
Registration Statement, or any amendment or supplement to the Registration Statement, or (ii) any
omission or alleged omission to state a material fact required to be stated therein or necessary to
make the statements therein not misleading, if and to the extent (and only to the extent) that the
statement or omission was made in reliance upon and in conformity with information relating to such
Selling Stockholder furnished in writing to the Company by such Selling Stockholder specifically
for use in connection with the preparation of such Registration Statement, prospectus, amendment or
supplement; provided, however, that the obligations of a Selling Stockholder
hereunder shall be limited to an amount equal to the net proceeds to such Selling Stockholder of
Registrable Shares sold in connection with such registration.

- 12 -

 

               (c) Each Indemnified Party shall give notice to the Indemnifying Party promptly after such
Indemnified Party has actual knowledge of any claim as to which indemnity may be sought, and shall
permit the Indemnifying Party to assume the defense of any such claim or any litigation resulting
therefrom; provided, that counsel for the Indemnifying Party, who shall conduct the defense
of such claim or litigation, shall be approved by the Indemnified Party (whose approval shall not
be unreasonably withheld, conditioned or delayed); and, provided, further, that the
failure of any Indemnified Party to give notice as provided herein shall not relieve the
Indemnifying Party of its obligations under this Section 2.5 except and only to the extent that the
Indemnifying Party is adversely prejudiced by such failure. The Indemnified Party may participate
in such defense at such party’s expense; provided, however, that the Indemnifying
Party shall pay such expense if the Indemnified Party reasonably concludes that representation of
such Indemnified Party by the counsel retained by the Indemnifying Party would be inappropriate due
to actual or potential differing interests between the Indemnified Party and any other party
represented by such counsel in such proceeding; provided further that in no event
shall the Indemnifying Party be required to pay the expenses of more than one law firm per
jurisdiction as counsel for the Indemnified Party. The Indemnifying Party also shall be
responsible for the expenses of such defense if the Indemnifying Party does not elect to assume
such defense. No Indemnifying Party, in the defense of any such claim or litigation shall, except
with the consent of each Indemnified Party, consent to entry of any judgment or enter into any
settlement which does not include as an unconditional term thereof the giving by the claimant or
plaintiff to such Indemnified Party of a release from all liability in respect of such claim or
litigation, and no Indemnified Party shall consent to entry of any judgment or settle such claim or
litigation without the prior written consent of the Indemnifying Party, which consent shall not be
unreasonably withheld, conditioned or delayed.

               (d) In order to provide for just and equitable contribution in circumstances in which the
indemnification provided for in this Section 2.5 is due in accordance with its terms but for any
reason is held to be unavailable to an Indemnified Party in respect to any losses, claims, damages
and liabilities referred to herein, then the Indemnifying Party shall, in lieu of indemnifying such
Indemnified Party, contribute to the amount paid or payable by such Indemnified Party as a result
of such losses, claims, damages or liabilities to which such party may be subject in such
proportion as is appropriate to reflect the relative fault of the Company on the one hand and the
Selling Stockholders on the other in connection with the statements or omissions which resulted in
such losses, claims, damages or liabilities, as well as any other relevant equitable
considerations. The relative fault of the Company and the Selling Stockholders shall be determined
by reference to, among other things, whether the untrue or alleged untrue statement of material
fact related to information supplied by the Company or the Selling Stockholders and the parties’
relative intent, knowledge, access to information and opportunity to correct or prevent such
statement or omission. The Company and the Selling Stockholders agree that it would not be just
and equitable if contribution pursuant to this Section 2.5(d) were determined by pro rata
allocation or by any other method of allocation which does not take account of the equitable
considerations referred to above. Notwithstanding the provisions of this Section 2.5(d), (i) in no
case shall any one Selling Stockholder be liable or responsible for any amount in excess of the net
proceeds received by such Selling Stockholder from the offering of Registrable Shares and (ii) the
Company shall be liable and responsible for any amount in excess of such proceeds;
provided, however, that no person guilty of fraudulent

- 13 -

 

misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be
entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.
Any party entitled to contribution will, promptly after receipt of notice of commencement of any
action, suit or proceeding against such party in respect of which a claim for contribution may be
made against another party or parties under this Section 2.5(d), notify such party or parties from
whom contribution may be sought, but the omission to notify such party or parties from whom
contribution may be sought shall not relieve such party from any other obligation it or they may
have thereunder or otherwise under this Section 2.5(d). No party shall be liable for contribution
with respect to any action, suit, proceeding or claim settled without its prior written consent,
which consent shall not be unreasonably withheld, conditioned or delayed.

               (e) The rights and obligations of the Company and the Selling Stockholders under this Section
2.5 shall survive the termination of this Agreement.

          2.6 Other Matters with Respect to Underwritten Offerings. In the event that
Registrable Shares are sold pursuant to a Registration Statement in an underwritten offering
pursuant to Section 2.1, the Company agrees to (a) enter into an underwriting agreement containing
customary representations and warranties with respect to the business and operations of the Company
and customary covenants and agreements to be performed by the Company, including without limitation
customary provisions with respect to indemnification by the Company of the underwriters of such
offering; (b) use its best efforts to cause its legal counsel to render customary opinions to the
underwriters with respect to the Registration Statement; and (c) use its best efforts to cause its
independent public accounting firm to issue customary “cold comfort letters” to the underwriters
with respect to the Registration Statement.

          2.7 Information by Holder. Each holder of Registrable Shares included in any
registration shall furnish to the Company such information regarding such holder and the
distribution proposed by such holder as the Company may reasonably request in writing and as shall
be required in connection with any registration, qualification or compliance referred to in this
Agreement.

          2.8 “Lock-Up” Agreement; Confidentiality of Notices. Each Stockholder, if requested
by the Company and the managing underwriter of the Initial Public Offering, shall not sell or
otherwise transfer or dispose of any Registrable Shares or other securities of the Company
(excluding securities acquired in the Initial Public Offering or in the public market after such
offering), without the consent of such underwriter, held by such Stockholder for a period of up to
180 days following the effective date of the Registration Statement for the Initial Public
Offering; provided, that all Other Holders, all stockholders of the Company then holding at
least 5% of the outstanding Common Stock (on an as-converted basis) and all officers and directors
of the Company enter into similar agreements; and provided further that any such lock-up agreement
shall provide that if the managing underwriter releases any shares from the lock-up with respect to
such offering prior to the scheduled expiration date, the managing underwriter shall
contemporaneously release a pro rata portion of the Registrable Shares from such lock-up.

- 14 -

 

     The Company may impose stop-transfer instructions with respect to the Registrable Shares or
other securities subject to the foregoing restriction until the end of such 180-day period.

     Any Stockholder receiving any written notice from the Company regarding the Company’s plans to
file a Registration Statement shall treat such notice confidentially and shall not disclose such
information to any person other than as necessary to exercise its rights under this Agreement.

          2.9 Limitations on Subsequent Registration Rights. The Company shall not, without the
prior written consent of Purchasers holding at least two-thirds of the Registrable Shares then held
by all Purchasers, enter into any agreement (other than this Agreement) with any holder or
prospective holder of any securities of the Company which grants such holder or prospective holder
rights to demand the registration of shares of the Company’s capital stock, or to include such
shares in a registration statement that would reduce the number of shares includable by the
Holders.

          2.10 Rule 144 Requirements. After the earliest of (i) the closing of the sale of
securities of the Company pursuant to a Registration Statement, (ii) the registration by the
Company of a class of securities under Section 12 of the Exchange Act, or (iii) the issuance by the
Company of an offering circular pursuant to Regulation A under the Securities Act, the Company
agrees to:

               (a) make and keep current public information about the Company available, as those terms are
understood and defined in Rule 144;

               (b) use its best efforts to file with the Commission in a timely manner all reports and other
documents required of the Company under the Securities Act and the Exchange Act (at any time after
it has become subject to such reporting requirements); and

               (c) furnish to any holder of Registrable Shares upon request (i) a written statement by the
Company as to its compliance with the reporting requirements of Rule 144 and of the Securities Act
and the Exchange Act (at any time after it has become subject to such reporting requirements), (ii)
a copy of the most recent annual or quarterly report of the Company, and (iii) such other reports
and documents of the Company as such holder may reasonably request to avail itself of any similar
rule or regulation of the Commission allowing it to sell any such securities without registration.

          2.11 Termination. All of the Company’s obligations to register Registrable Shares
under Sections 2.1 and 2.2 shall terminate upon the earlier of (i) five years after the closing of
the Initial Public Offering or (ii) the date on which no Stockholder holds any Registrable Shares.

     3. Right of First Refusal.

          3.1 Rights of Purchasers to Acquire Offered Securities.

- 15 -

 

               (a) The Company shall not issue, sell or exchange, agree to issue, sell or exchange, or
reserve or set aside for issuance, sale or exchange, any Offered Securities, unless in each such
case the Company shall have first complied with this Section 3.1. The Company shall deliver to
each Purchaser an Offer, which shall (i) identify and describe the Offered Securities, (ii)
describe the price and other terms upon which they are to be issued, sold or exchanged, and the
number or amount of the Offered Securities to be issued, sold or exchanged, (iii) identify the
persons or entities (if known) to which or with which the Offered Securities are to be offered,
issued, sold or exchanged, and (iv) offer to issue and sell to or exchange with such Purchaser that
is a Qualified Purchaser (A) such Qualified Purchaser’s Basic Amount and (B) such Qualified
Purchaser’s Undersubscription Amount.

               (b) To accept an Offer, in whole or in part, a Qualified Purchaser must deliver to the
Company, on or prior to the date 30 days after the date of delivery of the Offer, a Notice of
Acceptance providing a representation letter certifying that such Qualified Purchaser is an
accredited investor within the meaning of Rule 501 under the Act and indicating the portion of the
Qualified Purchaser’s Basic Amount that such Qualified Purchaser elects to purchase and, if such
Qualified Purchaser shall elect to purchase all of its Basic Amount, the Undersubscription Amount
(if any) that such Qualified Purchaser elects to purchase. If the Basic Amounts subscribed for by
all Qualified Purchasers are less than the total of all of the Basic Amounts available for
purchase, then each Qualified Purchaser who has set forth an Undersubscription Amount in its Notice
of Acceptance shall be entitled to purchase, in addition to the Basic Amounts subscribed for, the
Undersubscription Amount it has subscribed for; provided, however, that if the
Undersubscription Amounts subscribed for exceed the Available Undersubscription Amount, each
Qualified Purchaser who has subscribed for any Undersubscription Amount shall be entitled to
purchase only that portion of the Available Undersubscription Amount as the Undersubscription
Amount subscribed for by such Qualified Purchaser bears to the total Undersubscription Amounts
subscribed for by all Purchasers, subject to rounding by the Board of Directors to the extent it
deems reasonably necessary.

               (c) The Company shall have 90 days from the expiration of the period set forth in Section
3.1(b) to issue, sell or exchange all or any part of the Refused Securities, but only to the
offerees or purchasers described in the Offer (if so described therein) and only upon terms and
conditions (including, without limitation, unit prices and interest rates) set forth in the Offer.

               (d) In the event the Company shall propose to sell less than all the Refused Securities, then
each Qualified Purchaser may, at its sole option and in its sole discretion, reduce the number or
amount of the Offered Securities specified in its Notice of Acceptance to an amount that shall be
not less than the number or amount of the Offered Securities that the Qualified Purchaser elected
to purchase pursuant to Section 3.1(b) multiplied by a fraction, (i) the numerator of which shall
be the number or amount of Offered Securities the Company actually proposes to issue, sell or
exchange (including Offered Securities to be issued or sold to Qualified Purchasers pursuant to
Section 3.1(b) prior to such reduction) and (ii) the denominator of which shall be the original
amount of the Offered Securities. In the event that any Qualified Purchaser so elects to reduce
the number or amount of Offered Securities specified in its Notice of Acceptance, the Company may
not issue, sell or exchange more than the reduced

- 16 -

 

number or amount of the Offered Securities unless and until such securities have again been
offered to the Qualified Purchasers in accordance with Section 3.1(a).

               (e) Upon (i) the closing of the issuance, sale or exchange of all or less than all of the
Refused Securities or (ii) such other date agreed to by the Company and Qualified Purchasers who
have subscribed for a majority of the Offered Securities subscribed for by the Qualified
Purchasers, such Qualified Purchaser or Purchasers shall acquire from the Company and the Company
shall issue to such Qualified Purchaser or Purchasers, the number or amount of Offered Securities
specified in the Notices of Acceptance, as reduced pursuant to Section 3.1(d) if any of the
Qualified Purchasers has so elected, upon the terms and conditions specified in the Offer.

               (f) The purchase by the Qualified Purchasers of any Offered Securities is subject in all cases
to the preparation, execution and delivery by the Company and the Qualified Purchasers of a
purchase agreement relating to such Offered Securities reasonably satisfactory in form and
substance to the Qualified Purchasers and their respective counsel.

               (g) Any Offered Securities not acquired by the Qualified Purchasers or other persons in
accordance with Section 3.1(c) may not be issued, sold or exchanged until they are again offered to
the Qualified Purchasers under the procedures specified in this Agreement.

               (h) The rights of the Qualified Purchasers under this Section 3.1 shall not apply to:

                    (i) the issuance of any shares of Common Stock as a stock dividend to holders of Common Stock
or upon any subdivision or combination of shares of Common Stock;

                    (ii) the issuance of any shares of Common Stock upon conversion of shares of convertible
preferred stock;

                    (iii) the issuance of 103,533,435 (or such higher number as may be approved by the Board of
Directors of the Company, including a majority of the Investor Directors) shares of Common Stock,
or options with respect thereto, to employees, directors or officers of, or consultants to, the
Company or any of its subsidiaries pursuant to any plan, agreement or arrangement approved by the
Board of Directors of the Company and by a majority of the Investor Directors;

                    (iv) the issuance of securities solely in consideration for the acquisition (whether by merger
or otherwise) by the Company or any of its subsidiaries of all or substantially all of the stock or
assets of any other entity approved by the Board of Directors of the Company and by a majority of
the Investor Directors;

                    (v) the issuance of shares of Common Stock by the Company in a Qualified Public Offering;

- 17 -

 

                    (vi) the issuance of shares of Common Stock, or the grant of options or warrants therefor, in
connection with any present or future strategic partnerships, technology licenses or borrowing,
line of credit, leasing or similar financing arrangement approved by the Board of Directors of the
Company and by a majority of the Investor Directors; or

                    (vii) the issuance of shares of Series C Preferred pursuant to the Purchase Agreement.

          3.2 Termination. This Section 3 shall terminate upon the closing of a Qualified
Public Offering.

     4. Covenants. So long as at least 2,000,000 Shares (subject to appropriate adjustment
for stock splits, stock dividends, recapitalizations and similar events occurring after the date of
this Agreement) are outstanding, the Company covenants and agrees that it will perform and observe
the following covenants and provisions and will cause each Company Subsidiary to perform and
observe such of the following covenants and provisions as are applicable to such Company
Subsidiary.

          4.1 Payment of Taxes and Trade Debt. Pay and discharge all taxes, assessments and
governmental charges or levies imposed upon it or upon its income or profits or business, or upon
any properties belonging to it, prior to the date on which penalties attach thereto, and all lawful
claims, which, if unpaid, might become a lien or charge upon any properties of the Company or a
Company Subsidiary, other than those which are being contested in good faith if the Company shall
have set aside on its books and shall have provided, in accordance with generally accepted
accounting principles, adequate reserves with respect thereto; and pay in conformity with customary
trade terms, all lease obligations, all trade debt, and all other indebtedness incident to its
operations, except such as are being contested in good faith if the Company shall have set aside on
its books and shall have provided, in accordance with generally accepted accounting principles,
appropriate reserves with respect thereto.

          4.2 Maintenance of Insurance. Maintain with responsible and reputable insurance
companies or associations, insurance in such amounts and covering such risks as the Company
reasonably deems advisable.

          4.3 Compliance with Laws. Comply with all applicable laws, rules, regulations and
orders of any governmental authority, noncompliance with which could materially adversely affect
its business or condition, financial or otherwise, except non-compliance being contested in good
faith through appropriate proceedings so long as the Company shall have set up and funded
sufficient reserves, if any, required under generally accepted accounting principles with respect
to such items.

          4.4 Keeping of Records and Books of Account. Keep adequate records and books of
account, in which complete entries will be made in accordance with generally accepted accounting
principles consistently applied, reflecting all financial transactions of the Company, and in
which, for each fiscal year, all proper reserves for depreciation, depletion, obsolescence,
amortization, taxes, bad debts and other purposes in connection with its business shall be made.

- 18 -

 

          4.5 Preservation of Corporate Existence. Preserve and maintain its corporate
existence, rights, franchises and privileges in the jurisdiction of its incorporation, and qualify
and remain qualified as a foreign corporation in each jurisdiction in which such qualification is
required, unless the failure to so qualify does not and will not have a material and adverse effect
on the business, operations or financial condition of the Company; and preserve and maintain all
material licenses and other rights to use patents, processes, licenses, trademarks, trade names,
inventions, intellectual property rights or copyrights owned or possessed by it as the Company
deems reasonably necessary or advisable for it to conduct its business.

          4.6 Inspection. The Company shall permit each Significant Holder, or any authorized
representative thereof, to visit and inspect the properties of the Company, including its corporate
and financial records, and to discuss its business and finances with officers of the Company,
during normal business hours following reasonable notice and as often as may be reasonably
requested.

          4.7 Financial Statements and Other Information. The Company shall deliver to each
Significant Holder:

               (a) within 90 days after the end of each fiscal year of the Company, an audited balance sheet
of the Company as at the end of such year and audited statements of income and of cash flows of the
Company for such year, certified by certified public accountants selected by the Company, and
prepared in accordance with generally accepted accounting principles consistently applied;

               (b) within 30 days after the end of each of its fiscal quarters, its unaudited balance sheet
as at the end of such quarter and its unaudited statements of income for such fiscal quarter and
for the current fiscal year to the end of such fiscal quarter, setting forth in comparative form
its projected financial statements for the corresponding periods for the current fiscal year;

               (c) within 30 days after the end of each month (other than the last month of any fiscal year),
an unaudited balance sheet of the Company as at the end of such month and unaudited statements of
income and of cash flows of the Company for such month and for the current fiscal year to the end
of such month, setting forth in comparative form the Company’s projected financial statements for
the corresponding periods for the current fiscal year;

               (d) prior to the commencement of each new fiscal year, an operating plan and projected
financial statements for such fiscal year; and

               (e) with reasonable promptness, such other information and data as such Significant Holder may
from time to time reasonably request.

     The foregoing financial statements shall be prepared on a consolidated basis if the Company
then has any subsidiaries. The financial statements delivered pursuant to clauses (b) and (c)
shall be accompanied by a certificate of the chief financial officer of the Company stating that
such statements have been prepared in accordance with generally accepted accounting

- 19 -

 

principles consistently applied (except as noted) and fairly present the financial condition and
results of operations of the Company at the date thereof and for the periods covered thereby.

          4.8 Material Changes and Litigation. The Company shall promptly notify the Purchasers
of any material adverse change in the business, prospects, assets or condition, financial or
otherwise, of the Company and of any litigation or governmental proceeding or investigation brought
or, to the best of the Company’s knowledge, threatened against the Company, or against any officer,
director, key employee or principal stockholder of the Company which, if adversely determined,
would have a material adverse effect on the business, prospects, assets or condition (financial or
otherwise) of the Company.

          4.9 Agreements with Employees; Options; Stock Incentive Plan.

               (a) The Company shall require (i) all persons now or hereafter employed by the Company and
(ii) all independent contractors utilized by the Company who have access to confidential or
proprietary information of the Company to enter into non-disclosure and assignment of inventions
agreements substantially in the form of Exhibit H to the Purchase Agreement and shall
require all individuals employed at or above the director level or whose responsibilities are
technical in nature to enter into non-competition agreements substantially in the form of
Exhibit I to the Purchase Agreement, or such other form as may be approved by the Board of
Directors of the Company and by a majority of the Investor Directors.

               (b) The Company will not, without the approval of the Board of Directors of the Company and by
a majority of the Investor Directors, terminate, amend or waive any rights under any inventions,
confidentiality, non-competition or restricted stock agreement between the Company and any officer
of the Company.

               (c) Unless otherwise approved by the Board of Directors of the Company and by a majority of
the Investor Directors, all options or restricted stock granted or issued by the Company shall
become exercisable at the rate of 25% on the first anniversary of grant or issue and 2.0833% per
month thereafter over the subsequent three years so long as the holder continues to be an employee
or consultant of the Company.

          4.10 Board of Directors. The Company shall promptly reimburse in full each director
of the Company who is not an employee of the Company for all of his or her reasonable out-of-pocket
expenses incurred in attending each meeting of the Board of Directors of the Company or any
committee thereof or any other meeting or events attended on behalf of the Company or at the
Company’s request. The Board of Directors shall meet at least eight times per year, unless
otherwise agreed by a majority of the members of the Board of Directors, including the Investor
Directors.

          4.11 Insurance. The Company shall, upon the request of a majority of the Investor
Directors, obtain and maintain director and officer liability insurance for each of its directors
and officers in an amount to be determined by the Board of Directors of the Company.

          4.12 Related Party Transactions. The Company shall not enter into any agreement with
any officer or director of the Company, or any “affiliate” of such persons (as

- 20 -

 

such term is defined in the rules and regulations promulgated under the Securities Act),
including without limitation any agreement or other arrangement providing for the furnishing of
services by, rental of real or personal property from, or otherwise requiring payments to, any such
person or entity, without the consent of at least a majority of the members of the Company’s Board
of Directors having no interest in such agreement or arrangement.

          4.13 Executive Compensation. The approval of the Board of Directors of the Company
and a majority of the Investor Directors shall be required to (i) establish or increase the
compensation of executive officers of the Company or (ii) grant stock options to any officer of the
Company.

          4.14 Reservation of Common Stock. The Company shall reserve and maintain a sufficient
number of shares of Common Stock for issuance upon conversion of all of the outstanding Shares.

          4.15 International Investment and Trade in Services Survey Act. The Company shall use
its best efforts to file on a timely basis all reports required to be filed by it under 22 U.S.C.
Section 3104, or any similar statute, relating to a foreign person’s direct or indirect investment
in the Company.

          4.16 U.S. Real Property Holding Corporation. If at any time the Company shall become
a United States real property holding corporation, it shall notify the Purchasers of such event as
promptly as practicable. The Company will promptly provide to the Purchasers upon request a
statement described in Treasury Regulation §1.897-2(h) pursuant to Treasury Regulation
§1.1445-5(b)(4)(iii).

          4.17 Negative Covenants. So long as at least 2,000,000 Shares are outstanding
(subject to appropriate adjustment for stock splits, stock dividends, recapitalizations and similar
events occurring after the date of this Agreement), the Company shall not, without prior written
consent of either (i) the Board of Directors of the Company, including at least two of the Investor
Directors, or (ii) the holders of not less than 66 2/3% of the then outstanding Shares:

               (a) sell or grant an exclusive license to any of the Company’s or any Company Subsidiary’s
material intellectual property rights;

               (b) incur any indebtedness in excess of $100,000 in the aggregate, which indebtedness is not
covered by the Company’s annual budget;

               (c) organize or acquire any entity that is a subsidiary unless such subsidiary is wholly-owned
(directly or indirectly) by the Company;

               (d) acquire, directly or indirectly (including through a Company Subsidiary), (1) all or
substantially all of the properties or assets of any other person, company or entity or (2) any
investment in the securities of any other person, company or entity (other than short-term
marketable obligations issued or guaranteed by the United States of America with any commercial
bank or trust company); or

- 21 -

 

               (e) guarantee, or permit any Company Subsidiary to guarantee, directly or indirectly, any
indebtedness or obligations except for trade accounts of any Company Subsidiary arising in the
ordinary course of business.

          4.18 Directors’ Liability and Indemnification. The Company’s Certificate of
Incorporation and By-Laws, each as amended, shall provide (a) for elimination of the liability of
director to the maximum extent permitted by law and (b) for indemnification of directors for acts
on behalf of the Company to the maximum extent permitted by law.

          4.19 Qualified Small Business. The Company will use reasonable efforts to comply with
the reporting and recordkeeping requirements of Section 1202 of the Internal Revenue Code of 1986,
as amended (the “Code”), any regulations promulgated thereunder and any similar state laws and
regulations and agrees not to repurchase any stock of the Company if such repurchase would cause
the Shares not to so qualify as “Qualified Small Business Stock,” so long as the Company’s Board of
Directors determines that it is in the best interests of and not unduly burdensome to the Company
to comply with the provisions of Section 1202 of the Code.

          4.20 Termination of Covenants. All covenants of the Company contained in this Section
4 (other than the provisions of Section 4.11), shall terminate upon the closing of a Qualified
Public Offering.

     5. Confidentiality. Each Purchaser agrees it will keep confidential and will not
disclose, divulge or use for any purpose, other than to monitor its investment in the Company, any
Confidential Information, unless such Confidential Information (i) is known or becomes known to the
public in general (other than as a result of a breach of this Section 5 by such Purchaser), (ii) is
or has been independently developed or conceived by the Purchaser without use of the Company’s
Confidential Information or (iii) is or has been made known or disclosed to the Purchaser by a
third party without a breach of any obligation of confidentiality such third party may have to the
Company; provided, however, that a Purchaser may disclose Confidential Information
(a) to its attorneys, accountants, consultants, and other professionals to the extent necessary to
obtain their services in connection with monitoring its investment in the Company, (b) to any
prospective purchaser of any Shares from such Purchaser as long as such prospective purchaser
agrees to be bound by the provisions of this Section 5, (c) to any affiliate, partner, member,
stockholder or wholly owned subsidiary of such Purchaser, provided that such person is obligated
not to disclose, divulge or use any Confidential Information to the same extent as the Purchasers,
or (d) as may otherwise be required by law, provided that the Purchaser takes reasonable steps to
minimize the extent of any such required disclosure. Notwithstanding the foregoing, such
information shall not be deemed confidential for the purpose of enforcing this Agreement.

     6. Transfers of Rights; Calculation of Share Numbers.

          6.1 This Agreement, and the rights and obligations of each Purchaser hereunder, may be
assigned by such Purchaser to (a) any person or entity to which at least 250,000 Shares (subject to
appropriate adjustment for stock splits, stock dividends, recapitalizations and similar events
occurring after the date of this Agreement) are transferred by

- 22 -

 

such Purchaser, (b) to any Affiliated Party of such Purchaser, or (c) any person or entity
which is a partner, member or shareholder of such Purchaser, and, in each case, such transferee
shall be deemed a “Purchaser” for purposes of this Agreement; provided that such assignment of
rights shall be contingent upon the transferee providing a written instrument to the Company
notifying the Company of such transfer and assignment and agreeing in writing to be bound by the
terms of this Agreement to the same extent as the transferor. Notwithstanding the foregoing, any
person or entity to which any Shares or Registrable Shares are transferred by a Purchaser, whether
voluntarily or by operation of law, shall be bound by the obligations under Section 2.8 to the same
extent as if such transferee were a Purchaser hereunder and no Purchaser shall transfer any Shares
or Registrable Shares unless the transferee provides a written instrument to the Company notifying
the Company of such transfer and agreeing in writing to be bound by the terms of Section 2.8.

          6.2 In determining the number of Shares owned by a Purchaser for purposes of exercising rights
under this Agreement, (a) Shares owned by a Purchaser shall be deemed to include Shares which have
been converted into Common Stock so long as such Common Stock is owned by such Purchaser and (b)
all Shares held by affiliated entities or persons shall be aggregated together (provided that no
shares shall be attributed to more than one entity or person within any such group of affiliated
entities or persons), and such Purchaser may allocate the total number of Shares among such
Purchaser and its affiliated entities in such proportions as they may elect in their sole
discretion.

     7. General.

          7.1 Severability. The invalidity or unenforceability of any provision of this
Agreement shall not affect the validity or enforceability of any other provision of this Agreement.

          7.2 Specific Performance. In addition to any and all other remedies that may be
available at law in the event of any breach of this Agreement, each Purchaser shall be entitled to
specific performance of the agreements and obligations of the Company hereunder and to such other
injunctive or other equitable relief as may be granted by a court of competent jurisdiction.

          7.3 Governing Law. This Agreement shall be governed by and construed in accordance
with the internal laws of the State of Delaware (without reference to the conflicts of law
provisions thereof).

          7.4 Notices. All notices, requests, consents, and other communications under this
Agreement shall be in writing and shall be deemed delivered (i) three business days after being
sent by registered or certified mail, return receipt requested, postage prepaid or (ii) one
business day after being sent via a reputable nationwide overnight courier service guaranteeing
next business day delivery, in each case to the intended recipient as set forth below:

     If to the Company, at 100 Beaver Street, Suite 300, Waltham, MA 02453, Attention: President,
or at such other address as may have been furnished in writing by the Company to the other parties
hereto, with a copy to Wilmer Cutler Pickering Hale and Dorr LLP, 60 State Street, Boston, MA
02109, Attention: Steven D. Singer, Esq.;

- 23 -

 

If to a Purchaser, at its address set forth on Exhibit A, or at such other address as
may have been furnished in writing by such Purchaser to the other parties hereto, and if to Venrock
Associates with a copy to Cooley Godward LLP, One Freedom Square, Reston Tower Center, 11951
Freedom Drive, Reston, VA 21090-5656, Attention: Ryan E. Naftulin, Esq., and if to a holder of
Series A Preferred, with a copy to Nutter McClennen & Fish LLP, World Trade Center West, 155
Seaport Boulevard, Boston, MA 02210, Attention: Richard N. Kimball, Esq.;

     If to a Common Stockholder, at his or her address set forth on Exhibit B, or at such
other address as may have been furnished in writing by such Common Stockholder to the other parties
hereto; or

     If to GE, at General Electric Capital Corporation, 401 Merritt 7, Suite 23, Norwalk, CT
06851-1177, Attention: Risk Manager.

     Any party may give any notice, request, consent or other communication under this Agreement
using any other means (including, without limitation, personal delivery, messenger service,
telecopy, first class mail or electronic mail), but no such notice, request, consent or other
communication shall be deemed to have been duly given unless and until it is actually received by
the party for whom it is intended. Any party may change the address to which notices, requests,
consents or other communications hereunder are to be delivered by giving the other parties notice
in the manner set forth in this Section 7.4.

          7.5 Complete Agreement; Waiver Under Old Investor Rights Agreement. The Company and
the holders of at least 66 2/3% of the voting power of the Shares held by the Purchasers (as
defined in the Old Investor Rights Agreement) hereby (A) agree that, as of the date of this
Agreement, (i) the Old Investor Rights Agreement is hereby amended in its entirety by this
Agreement, (ii) the provisions of the Old Investor Rights Agreement shall no longer be of any force
or effect and (iii) this Agreement constitutes the only agreement, contract or understanding among
the Series A Purchasers, the Series B Purchasers, the Series C Purchasers, Comerica, GE and the
Common Stockholders relating to all or part of the subject matter of this Agreement and (B) waive
their rights under Section 3.1 of the Old Investor Rights Agreement with respect to the sale of
shares of Series C Preferred.

          7.6 Amendments and Waivers. This Agreement may be amended or terminated and the
observance of any term of this Agreement may be waived with respect to all parties to this
Agreement (either generally or in a particular instance and either retroactively or prospectively),
with the written consent of the Company and Purchasers holding Shares representing at least 66 2/3%
of the voting power of all Shares then held by Purchasers; provided, however, Exhibit B may
be amended by the Company from time to time to add additional Common Stockholders upon the
designation of the Board of Directors including a majority of the Investor Directors, without the
consent of the other parties hereto. Notwithstanding the foregoing, this Agreement may not be
amended or terminated and the observance of any term of this Agreement may not be waived with
respect to any Purchaser without the written consent of such Purchaser unless such amendment,
termination or waiver applies to all Purchasers in the same fashion (it being agreed that a waiver
of the provisions of Section 3 with respect to a particular transaction shall be deemed to apply to
all Qualified

- 24 -

 

Purchasers in the same fashion if such waiver does so by its terms, notwithstanding the fact
that certain Qualified Purchasers may nonetheless, by agreement with any Company, purchase
securities in such transaction). Any amendment, termination or waiver effected in accordance with
this Section 7.6 shall be binding on all parties hereto, even if they do not execute such consent.
No waivers of or exceptions to any term, condition or provision of this Agreement, in any one or
more instances, shall be deemed to be, or construed as, a further or continuing waiver of any such
term, condition or provision. Notwithstanding this Section 7.6, the rights of first refusal
established by Section 3 hereof may be amended, or any provision waived with respect to a
particular transaction, with the written consent of the Company and the Qualified Purchasers
holding two-thirds (2/3) of the Registrable Shares held by all Qualified Purchasers; provided,
however, that notwithstanding any such waiver, in the event that a Purchaser actually purchases
Offered Securities in any such transaction, then each other Qualified Purchaser shall be permitted
to participate on a pro rata basis based on the other Qualified Purchaser purchasing the largest
portion of such Qualified Purchaser’s pro rata share.

          7.7 Pronouns. Whenever the context may require, any pronouns used in this Agreement
shall include the corresponding masculine, feminine or neuter forms, and the singular form of nouns
and pronouns shall include the plural, and vice versa.

          7.8 Counterparts; Facsimile Signatures. This Agreement may be executed in any number
of counterparts, each of which shall be deemed to be an original, and all of which together shall
constitute one and the same document. This Agreement may be executed by facsimile signatures.

          7.9 Section Headings and References. The section headings are for the convenience of
the parties and in no way alter, modify, amend, limit or restrict the contractual obligations of
the parties. Any reference in this agreement to a particular section or subsection shall refer to
a section or subsection of this Agreement, unless specified otherwise.

[Remainder of Page Intentionally Left Blank]

- 25 -

 

     Executed as of the date first written above.

	 	 	 	 	 	 	 
	 	 	COMPANY:	 	 
	 
	 	 	 	 	 	 
	 	 	ADNEXUS THERAPEUTICS, INC.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ John D. Mendlein	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	John D. Mendlein	 	 
	 

	 	 	 	President and Chief Executive Officer	 	 
	 
	 	 	 	 	 	 
	 	 	PURCHASERS:	 	 
	 
	 	 	 	 	 	 
	 	 	HBM BIOVENTURES (CAYMAN) LTD.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ John Arnold	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	John Arnold	 	 
	 

	 	 	 	Chairman and Managing Director	 	 
	 
	 	 	 	 	 	 
	 	 	VENROCK ASSOCIATES IV, L.P.	 	 
	 
	 	 	 	 	 	 
	 	 	By its General Partner, Venrock Management IV,
LLC	 	 
	 
	 	 	 	 	 	 
	 	 	VENROCK PARTNERS, L.P.	 	 
	 
	 	 	 	 	 	 
	 	 	By its General Partner, Venrock Partners

      Management, LLC	 	 
	 
	 	 	 	 	 	 
	 	 	VENROCK ENTREPRENEURS FUND IV, L.P.	 	 
	 
	 	 	 	 	 	 
	 	 	By its General Partner, VEF Management IV, LLC	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Anders Hove	 	 
	 

	 	 	 	 	 	 
	 	 	Name: Anders Hove	 	 
	 	 	Title: Member	 	 

Signature Page to Second Amended and
Restated Investor Rights Agreement

 

 

	 	 	 	 	 	 	 
	 	 	FLAGSHIP
VENTURES	 	 
	 
	 	 	 	 	 	 
	 	 	APPLIED GENOMIC TECHNOLOGY	 	 
	 	 	CAPITAL FUND, L.P.	 	 
	 	 	AGTC ADVISORS FUND, L.P.	 	 
	 
	 	 	 	 	 	 
	 	 	Each by its General Partner, AGTC Partners, L.P.	 	 
	 
	 	 	 	 	 	 
	 	 	By its General Partner, NewcoGen Group Inc.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Noubar B. Afeyan	 	 
	 

	 	 	 	 	 	 
	 

	 	Name:
	 	Noubar B. Afeyan	 	 
	 

	 	Title:
	 	President	 	 
	 
	 	 	 	 	 	 
	 	 	FLAGSHIP VENTURES	 	 
	 
	 	 	 	 	 	 
	 	 	NEWCOGEN GROUP LLC	 	 
	 	 	NEWCOGEN EQUITY INVESTORS LLC	 	 
	 	 	NEWCOGEN-PE LLC	 	 
	 	 	NEWCOGEN-ELAN LLC	 	 
	 	 	ST NEWCOGEN LLC	 	 
	 	 	NEWCOGEN – LONG REIGN HOLDING LLC	 	 
	 
	 	 	 	 	 	 
	 	 	Each by its Manager, NewcoGen Group Inc.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Noubar B. Afeyan	 	 
	 

	 	 	 	 	 	 
	 

	 	Name:
	 	Noubar Afeyan	 	 
	 

	 	Title:
	 	President	 	 

 

 

	 	 	 	 	 	 	 
	 	 	POLARIS VENTURE PARTNERS IV, L.P.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	Polaris Venture Management Co. IV, L.L.C.	 	 
	 

	 	 	 	its general partner	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ William E. Bilodeau	 	 
	 

	 	 	 	 	 	 
	 

	 	Name:
	 	William E. Bilodeau	 	 
	 

	 	Title:
	 	Attorney-in-fact	 	 
	 
	 	 	 	 	 	 
	 	 	POLARIS VENTURE PARTNERS	 	 
	 	 	ENTREPRENEURS’ FUND IV, L.P.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	Polaris Venture Management Co. IV, L.L.C.	 	 
	 

	 	 	 	its general partner	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ William E. Bilodeau	 	 
	 

	 	 	 	 	 	 
	 

	 	Name:
	 	William E. Bilodeau	 	 
	 

	 	Title:
	 	Attorney-in-fact	 	 
	 
	 	 	 	 	 	 
	 	 	ATLAS VENTURE FUND V, L.P.	 	 
	 	 	ATLAS VENTURE PARALLEL FUND V-A, C.V.	 	 
	 	 	ATLAS VENTURE ENTREPRENEURS’ FUND V, L.P.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	Atlas Venture Associates V, L.P.	 	 
	 

	 	 	 	their general partner	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	Atlas Venture Associates V, Inc.	 	 
	 

	 	 	 	its general partner	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Jeanne Larkin Henry	 	 
	 

	 	 	 	 	 	 
	 

	 	Name:	 	 	 	 
	 

	 	 	 	 	 	 
	 

	 	Title:
	 	Vice President	 	 

 

 

	 	 	 	 	 	 	 
	 	 	ATLAS VENTURE FUND VI, L.P.	 	 
	 	 	ATLAS VENTURE ENTREPRENEURS’ FUND VI, L.P.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	Atlas Venture Associates VI, L.P.	 	 
	 

	 	 	 	their general partner	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	Atlas Venture Associates VI, Inc.	 	 
	 

	 	 	 	its general partner	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Jeanne Larkin Henry	 	 
	 

	 	 	 	 	 	 
	 

	 	Name:	 	 	 	 
	 

	 	 	 	 	 	 
	 

	 	Title:
	 	Vice President	 	 
	 
	 	 	 	 	 	 
	 	 	ATLAS VENTURE FUND VI GMBH & CO. KG	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	Atlas Venture Associates VI, L.P.	 	 
	 

	 	 	 	its managing limited partner	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	Atlas Venture Associates VI, Inc.	 	 
	 

	 	 	 	its general partner	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Jeanne Larkin Henry	 	 
	 

	 	 	 	 	 	 
	 

	 	Name:	 	 	 	 
	 

	 	 	 	 	 	 
	 

	 	Title:
	 	Vice President	 	 
	 
	 	 	 	 	 	 
	 	 	        /s/ Frank Lee	 	 
	 	 	 	 	 
	 	 	Frank Lee	 	 
	 
	 	 	 	 	 	 
	 	 	GENERAL ELECTRIC CAPITAL CORPORATION	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 

	 	 	 	 	 	 
	 

	 	Name:	 	 	 	 
	 

	 	 	 	 	 	 
	 

	 	Title:	 	 	 	 
	 

	 	 	 	 	 	 

 

 

	 	 	 	 	 	 	 
	 	 	COMERICA BANK	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 

	 	 	 	 	 	 
	 

	 	Name:	 	 	 	 
	 

	 	 	 	 	 	 
	 

	 	Title:	 	 	 	 
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	COMMON STOCKHOLDERS:	 	 
	 
	 	 	 	 	 	 
	 	 	/s/ Frank Lee	 	 
	 	 	 	 	 
	 	 	Frank Lee	 	 
	 
	 	 	 	 	 	 
	 	 	 	 	 
	 	 	Gordon Wong	 	 
	 
	 	 	 	 	 	 
	 	 	 	 	 
	 	 	Patrick Gage	 	 
	 
	 	 	 	 	 	 
	 	 	 	 	 
	 	 	Steven Benkovic	 	 

 

 

EXHIBIT A

List of Purchasers

Name and Address

Venrock Associates

30 Rockefeller Plaza

Suite 5508

New York, NY 10112-0256

Flagship Ventures:

Applied Genomic Technology

Capital Fund, L.P.

AGTC Advisors Fund, L.P.

NewcoGen Group LLC

NewcoGen Equity Investors LLC

NewcoGen PE LLC

NewcoGen Elan LLC

ST NewcoGen LLC

NewcoGen Long Reign Holding LLC

150 Cambridge Park Drive

10th Floor

Cambridge, MA 02140

Polaris Venture Partners IV, L.P.

Polaris Venture Partners Entrepreneurs’ Fund IV, L.P.

1000 Winter Street

Suite 3350

Waltham, MA 02451

Atlas Venture Fund V, L.P.

Atlas Venture Parallel Fund V-A, C.V.

Atlas Venture Entrepreneurs’ Fund V, L.P.

Atlas Venture Fund VI, L.P.

Atlas Venture Entrepreneurs’ Fund VI, L.P.

Atlas Venture Fund VI GmbH & Co. KG

890 Winter Street

Suite 320

Waltham, MA 02451

General Electric Capital Corporation

401 Merritt 7, Suite 23

Norwalk, CT 06851-1177

A - 1 

 

Frank Lee

6 Norfolk Road

Chestnut Hill, MA 02467

HBM BioVentures (Cayman) Ltd.

Centennial Towers, 3rd Floor

2454 West Bay Road

Grand Cayman, Cayman Islands

B - 1 

 

EXHIBIT B

Common Stockholders

Frank Lee

6 Norfolk Road

Chestnut Hill, MA 02467

Gordon Wong

134 Clinton Road

Brookline, MA 02445

Patrick Gage

340 Baintree Road

Rosemont, PA 19010

Steven Benkovic

771 Teaberry Lane

State College, PA 16803e

B - 1 

 

ADNEXUS THERAPEUTICS, INC.

AMENDMENT NO. 1 TO SECOND AMENDED AND RESTATED INVESTOR RIGHTS

AGREEMENT

     This AMENDMENT NO. 1 TO SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (“Amendment”),
dated as of August 13, 2007, amends that certain Second Amended and Restated Investor Rights
Agreement (“Agreement”), dated as of July 11, 2007, by and among Adnexus Therapeutics, Inc., a
Delaware corporation (the “Company”), the Purchasers (as defined therein), the Common Stockholders
(as defined therein), General Electric Capital Corporation (“GE”) and Comerica Bank. Capitalized
terms used and not defined herein shall have the meanings set forth in the Agreement.

     WHEREAS, prior to the date hereof, the Company and the Purchasers entered into a Series C
Convertible Preferred Stock Purchase Agreement, dated as of July 11, 2007;

     WHEREAS, prior to the date hereof, the Company and the parties hereto entered into the
Agreement;

     WHEREAS, the Company, the Purchasers, GE and Trink Inc. (“Trink”) have entered into an
Amendment No. 1 to Series C Convertible Preferred Stock Purchase Agreement of even date herewith
(the “Amendment to Purchase Agreement”);

     WHEREAS, as a condition precedent to the sale of shares of the Company’s Series C Convertible
Preferred Stock, $.001 par value per share (“Series C Preferred Stock”), pursuant to the Amendment
to Purchase Agreement, GE and Trink have required that the Agreement be amended in the manner set
forth below; and

     WHEREAS, pursuant to Section 7.6 of the Agreement, any amendment of the Agreement requires the
written consent of the Company and Purchasers holding Shares representing at least 66 2/3% of the
voting power of all Shares then held by Purchasers.

     NOW, THEREFORE, in consideration of the mutual covenants contained herein and the consummation
of the purchase and sale of shares of Series C Preferred Stock pursuant to the Amendment to
Purchase Agreement, and for other valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, GE, Trink and the other parties hereto, representing at least 66 2/3% of the
voting power of all Shares held by Purchasers, agree as follows:

     1. The Agreement is hereby amended such that Trink shall be a party to the Agreement as a
Purchaser thereunder.

     2. The definition of “Purchase Agreement” contained in Section 1 of the Agreement is hereby
deleted in its entirety and replaced with the following:

          “Purchase Agreement” means the Series C Convertible Preferred Stock Purchase
Agreement, dated as of July 11, 2007, between the Company and the Purchasers, as amended from time
to time.

 

 

     3. The definition of “Series C Purchaser” contained in Section 1 of the Agreement is hereby
deleted in its entirety and replaced with the following:

          “Series C Purchaser” means an individual or entity who purchases shares of Series C
Preferred pursuant to the Purchase Agreement.

     4. The Company and the undersigned Qualified Purchasers holding two-thirds of the Registerable
Shares held by all Qualified Purchasers hereby waive, on behalf of all Qualified Purchasers, their
rights under Section 3 of the Agreement with respect to the sale of shares of Series C Preferred
Stock pursuant to the Amendment to Purchase Agreement.

     5. Upon the effectiveness of this Amendment, on and after the date hereof, each reference in
the Agreement to “this Agreement,” “hereunder,” “hereof,” “herein” or words of like import, and
each reference in the other documents entered into in connection with the Agreement, shall mean and
be a reference to the Agreement, as amended hereby. Except as specifically amended above, the
Agreement shall remain in full force and effect and is hereby ratified and confirmed.

     6. This Amendment may be executed in one or more counterparts, each of which shall for all
purposes be deemed to be an original and all of which shall constitute the same document.

     7. This Agreement shall be governed by and construed in accordance with the internal laws of
the State of Delaware (without reference to the conflicts of law provisions thereof).

[Remainder of Page Intentionally Left Blank]

 - 2 - 

 

 

     IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed as an
instrument under seal as of the date first above written.

	 	 	 	 	 
	 	COMPANY:

ADNEXUS THERAPEUTICS, INC.

 	 
	 	By:  	/s/ John D. Mendlein
 	 
	 	 	John D. Mendlein 	 
	 	 	President and Chief Executive Officer 	 
	 

Signature Page to Amendment No. 1 to Second Amended and Restated Investor Rights Agreement

 

 

	 	 	 	 	 
	 	PURCHASERS: 

HBM BIOVENTURES (CAYMAN) LTD.

 	 
	 	By:  	/s/ John Arnold
 	 
	 	 	John Arnold      	 
	 	 	Chairman and Managing Director 	 
	 
	 	VENROCK ASSOCIATES IV, L.P. 

By its General Partner, Venrock Management IV, LLC

VENROCK PARTNERS, L.P.

By its General Partner, Venrock Partners Management, LLC

	 
	 	 	 
	 	VENROCK ENTREPRENEURS FUND IV, L.P.

By its General Partner, VEF Management IV, LLC

 	 
	 	By:  	/s/ Anders Hove
 	 
	 	 	Name:  	Anders Hove 	 
	 	 	Title:  	Member 	 
	 

Signature Page to Amendment No. 1 to Second Amended and Restated Investor Rights Agreement

 

 

	 	 	 	 	 	 	 
	 	 	FLAGSHIP VENTURES	 	 
	 
	 	 	 	 	 	 
	 	 	APPLIED GENOMIC TECHNOLOGY CAPITAL FUND, L.P.	 	 
	 	 	AGTC ADVISORS FUND, L.P.	 	 
	 
	 	 	 	 	 	 
	 	 	Each by its General Partner, AGTC Partners, L.P.	 	 
	 
	 	 	 	 	 	 
	 	 	By its General Partner, NewcoGen Group Inc.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Noubar B. Afeyan	 	 
	 

	 	Name:
	 	 

Noubar B. Afeyan
	 	 
	 

	 	Title:
	 	President	 	 
	 
	 	 	 	 	 	 
	 	 	FLAGSHIP VENTURES	 	 
	 
	 	 	 	 	 	 
	 	 	NEWCOGEN GROUP LLC	 	 
	 	 	NEWCOGEN EQUITY INVESTORS LLC	 	 
	 	 	NEWCOGEN-PE LLC	 	 
	 	 	NEWCOGEN-ELAN LLC	 	 
	 	 	ST NEWCOGEN LLC	 	 
	 	 	NEWCOGEN – LONG REIGN HOLDING LLC	 	 
	 
	 	 	 	 	 	 
	 	 	Each by its Manager, NewcoGen Group Inc.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Noubar B. Afeyan	 	 
	 

	 	Name:
	 	 

Noubar Afeyan
	 	 
	 

	 	Title:
	 	President	 	 

Signature Page to Amendment No. 1 to Second Amended and Restated Investor Rights Agreement

 

 

	 	 	 	 	 	 	 
	 	 	POLARIS VENTURE PARTNERS IV, L.P.	 	 
	 
	 	 	 	 	 	 
	 	 	By: Polaris Venture Management Co. IV, L.L.C.	 	 
	 	 	       its general partner	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ William E. Bilodeau	 	 
	 

	 	Name:
	 	 

William E. Bilodeau
	 	 
	 

	 	Title:
	 	Attorney-in-fact	 	 
	 
	 	 	 	 	 	 
	 	 	POLARIS VENTURE PARTNERS ENTREPRENEURS’ FUND IV, L.P.	 	 
	 
	 	 	 	 	 	 
	 	 	By: Polaris Venture Management Co. IV, L.L.C.	 	 
	 	 	       its general partner	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ William E. Bilodeau	 	 
	 

	 	Name:
	 	 

William E. Bilodeau
	 	 
	 

	 	Title:
	 	Attorney-in-fact	 	 

Signature Page to Amendment No. 1 to Second Amended and Restated Investor Rights Agreement

 

 

	 	 	 	 	 	 	 
	 	 	ATLAS VENTURE FUND V, L.P.	 	 
	 	 	ATLAS VENTURE PARALLEL FUND V-A, C.V.	 	 
	 	 	ATLAS VENTURE ENTREPRENEURS’ FUND V, L.P.	 	 
	 
	 	 	 	 	 	 
	 	 	By: Atlas Venture Associates V, L.P.	 	 
	 	 	       their general partner	 	 
	 
	 	 	 	 	 	 
	 	 	By: Atlas Venture Associates V, Inc.	 	 
	 	 	       its general partner	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Jean Francois Formela	 	 
	 

	 	Name:
	 	 

	 	 
	 

	 	Title:
	 	 

	 	 
	 
	 	 	 	 	 	 
	 	 	ATLAS VENTURE FUND VI, L.P.	 	 
	 	 	ATLAS VENTURE ENTREPRENEURS’ FUND VI, L.P.	 	 
	 
	 	 	 	 	 	 
	 	 	By: Atlas Venture Associates VI, L.P.	 	 
	 	 	       their general partner	 	 
	 
	 	 	 	 	 	 
	 	 	By: Atlas Venture Associates VI, Inc.	 	 
	 	 	       its general partner	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Jean Francois Formela	 	 
	 

	 	Name:
	 	 

	 	 
	 

	 	Title:
	 	 

	 	 
	 
	 	 	 	 	 	 
	 	 	ATLAS VENTURE FUND VI GMBH & CO. KG	 	 
	 
	 	 	 	 	 	 
	 	 	By: Atlas Venture Associates VI, L.P.	 	 
	 	 	       its managing limited partner	 	 
	 
	 	 	 	 	 	 
	 	 	By: Atlas Venture Associates VI, Inc.	 	 
	 	 	       its general partner	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Jean Francois Formela	 	 
	 

	 	Name:
	 	 

	 	 
	 

	 	Title:
	 	 

	 	 

Signature Page to Amendment No. 1 to Second Amended and Restated Investor Rights Agreement

 

 

	 	 	 	 	 	 	 
	 

	 	 	 	/s/ Frank Lee	 	 
	 	 	 	 	 
	 	 	Frank Lee	 	 
	 
	 	 	 	 	 	 
	 	 	GENERAL ELECTRIC CAPITAL CORPORATION	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 

	 	Name:
	 	 

	 	 
	 

	 	Title:
	 	 

	 	 
	 

	 	 	 	 

	 	 
	 
	 	 	 	 	 	 
	 	 	COMERICA BANK	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 

	 	Name:
	 	 

	 	 
	 

	 	Title:
	 	 

	 	 
	 

	 	 	 	 

	 	 
	 
	 	 	 	 	 	 
	 	 	TRINK INC.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Timothy Rink	 	 
	 

	 	Name:
	 	 

	 	 
	 

	 	Title:
	 	 

	 	 
	 

	 	 	 	 

	 	 
	 
	 	 	 	 	 	 
	 	 	COMMON STOCKHOLDERS:	 	 
	 
	 	 	 	 	 	 
	 

	 	 	 	/s/ Frank Lee	 	 
	 	 	 	 	 
	 	 	Frank Lee	 	 
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	 	 	 
	 	 	Gordon Wong	 	 
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	 	 	 
	 	 	Patrick Gage	 	 
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	 	 	 
	 	 	Steven Benkovic	 	 

Signature Page to Amendment No. 1 to Second Amended and Restated Investor Rights Agreementexv10w23

 

Exhibit 10.23

April 24, 2005

Dr. John Mendlein

99 Harbour Square #2708

Toronto, Canada M5J 2H2

April 24, 2005

Dear John,

     I am pleased to confirm our offer of employment for the position of Chief Executive Officer of
Compound Therapeutics, Incorporated (the “Company”), reporting to the Board of Directors. You will
also be elected to the Board of Directors. The following is a summary of the terms of your
employment, which shall be binding on you and the Company upon your acceptance of this offer as
provided in the last paragraph below:

     Your base salary will be at an annualized rate of $310,000 per year, payable in accordance
with the Company’s normal payroll practices. You will have a bonus opportunity set at 30% of base
salary for 2005-6, based upon corporate goals to be agreed with the Board of Directors. Your base
salary and other compensation will be reviewed annually by the Compensation Committee of the Board;
provided, however, that such salary shall not be subject to decrease other than in accordance with
the parenthetical of clause (iii) of the definition of “Good Reason” below. The Company will pay
you a signing bonus of $5,000 upon commencement of your employment.

     You will receive stock options for 5% of the Company’s fully diluted outstanding share capital
at the next Board of Directors meeting (approximately 3.5 million shares based on the number of
shares currently outstanding). The exercise price of the options will be at fair market value on
your first date of employment. The options will vest over four years with the first 25% vesting on
your one-year anniversary of employment. Vesting will continue quarterly on a straight-line basis
over the remaining 12 quarters. The options will be governed by the Compound Therapeutics,
Incorporated 2002 Stock Incentive Plan (the “Stock Option Plan”) and any applicable grant
documents; provided, however, that, upon termination of your employment, you will have three years
following the date of employment termination in which to exercise any then vested options,
regardless of the reason. You may elect to receive all or a portion of your equity grants in the
form of restricted stock, for which the purchase price will equal the fair market value on the date
of grant.

     In the event of a Change of Control (as defined below), the vesting schedule for your options
will be accelerated as follows: (a) 50% of the options or restricted shares that are not then
vested will be accelerated and become vested and exercisable (or free from the Company’s repurchase
option, as applicable) upon the consummation of the Change of Control; and (b) if, during the three
months prior to or during the twelve months following the Change of Control, your employment with
the Company is

1365 Main Street
• Waltham, MA 02451 • T: (781) 891-3745
• F: (781) 891-3796 •
www.compundtherapeutics. com

 

 

terminated by the Company (or the acquiring company) without Cause (as defined below), or by
you for Good Reason (as defined below), then all remaining unvested options or restricted shares
shall vest and become exercisable (or free from the Company’s repurchase option, as applicable)
upon such termination. The acceleration provisions described herein may be waived by you at any
time. In the event your employment with the Company is terminated due to your death or disability
(as defined below), 12.5% of the shares subject to any stock options or restricted stock grants
shall vest and become exercisable (or free from the Company’s repurchase option, as applicable) on
the date of such event.

     In the event, at any time, your employment is terminated by the Company without Cause or by
you for Good Reason, then, provided you execute a mutually acceptable release of claims as drafted
by counsel to the Company and such release becomes binding, (i) you will be entitled to continue to
receive as severance pay your base salary at the then current rate for a period of twelve months
following the date of termination, (ii) assuming that you are eligible to continue to participate
in the Company’s medical and dental insurance plans pursuant to the law known as COBRA, the Company
will continue to contribute to your medical and dental insurance premiums at the same rate as was
in effect just prior to your employment termination for a period of twelve (12) months following
the date of termination, and (iii) 25% of the original number of shares subject to any options or
restricted stock grants shall vest and become exercisable (or free from the Company’s repurchase
option, as applicable) on the date of such employment termination.

     To the extent the foregoing paragraph constitutes a “nonqualified deferred compensation plan”
as defined in Section 409A(d)(1) of the Code, neither you nor the Company shall have the right to
accelerate or to defer the delivery of the payments to be made under the foregoing paragraph;
provided, however, that if you are a “specified employee” as defined in Section
409A(a)(2)(B)(i) of the Internal Revenue Code of 1986, as amended (the “Code”), and any of the
payments to be made to you under the foregoing paragraph constitute “nonqualified deferred
compensation” within the meaning of Section 409A of the Code, then the commencement of the delivery
of any such payments will be delayed to the date that is 6 months after the date of employment
termination.

     The Company will also reimburse your reasonable moving and relocation expenses, up to a limit
of twenty thousand dollars ($20,000). In addition, until November 15, 2005, all reasonable costs
(up to a maximum of $3,000 per month) associated with your temporary housing will be reimbursed
directly by the Company. In the event either of the foregoing payments is taxable to you, the
Company will make a “gross-up” payment to you with respect to such tax liability.

     Promptly following commencement of your employment with the Company, the Company will seek to
obtain, and thereafter will maintain, director and officer liability insurance for each of its
directors and officers.

     You will be eligible to participate in the Company’s employee benefits program as generally
provided by the Company’s policies and benefit plans for the Company’s

1365 Main Street
• Waltham, MA 02451 • T: (781) 891-3745
• F: (781) 891-3796 •
www.compundtherapeutics. com

 - 2 - 

 

senior executives. As part of your employment with the Company, you have and will be exposed
to, and provided with, valuable confidential and/or trade secret information concerning the Company
and its present or prospective clients. As a result, in order to protect the Company’s legitimate
business interests, you agree, as a condition of your employment, to enter into an Employee
Non-Disclosure and a Non-Competition and Non-Solicitation Agreement. These documents will be
provided for your review and execution by the first day of your employment.

     Upon the Company’s consummation of an initial public offering of the Company’s common stock
pursuant to an effective registration statement under the Securities Act of 1933, as amended (an
“IPO”), the Company agrees to enter into an agreement with you regarding a Change of Control of the
Company. This agreement will provide that the Company will make a “gross-up” payment to you such
that, in the event certain tax penalties are imposed on you as a result of the provisions of
Sections 280G and/or 4999 of the Code, your net after-tax payments and benefits shall be equal to
what you would have received absent the penalty tax. In the event that the Company undergoes a
Change of Control prior to an IPO, the Company agrees, upon your request, that it will seek the
requisite approval by its stockholders, and encourage that they grant such approval, of the
payments proposed to be made to you in connection with such Change of Control in order to prevent
having the payments characterized as “parachute payments” under Sections 280G and 4999 of the Code.
In connection with the obtaining of such approval, you agree to undertake any such waivers that
may be required of you in order for the Company to validly seek the approval of its stockholders.
In the event that (i) you choose to waive the acceleration provisions described in the fourth
paragraph of this letter agreement in order to avoid the tax penalties described above, (ii) the
requisite stockholder approval is not obtained, and (iii) your employment is terminated by the
Company without Cause in connection with the Change of Control so as to give rise to the right
acceleration specified above, the Company agrees to enter into a consulting or advisory
relationship with you following the consummation of such Change in Control such that any unvested
stock options or restricted shares shall continue to vest in accordance with the terms of any
applicable stock option or restricted stock agreements. The Company agrees to maintain such
relationship with you in good faith, provided you continue to provide bona fide consulting or
advisory services to the Company, until such time as all options or restricted shares which were
unvested as of the consummation of such Change of Control become fully vested.

     Nothing herein shall create any obligation on the part of the Company, or any other person, to
continue your employment. Your employment with the Company is at will which means either the
Company or you may terminate your employment relationship with the Company at any time or for any
or no reason, with or without cause, and with or without notice, subject to the terms of this
letter agreement. The Company reserves the right to alter, supplement or rescind its employment
procedures, benefits or policies (other than the employment at-will policy) at any time in its sole
and absolute discretion and without notice, subject to the terms of this letter agreement.

     In accepting employment with the Company, you are representing that you are under no
contractual or other restrictions or obligations that are inconsistent with your

1365 Main Street
• Waltham, MA 02451 • T: (781) 891-3745
• F: (781) 891-3796 •
www.compundtherapeutics. com

 - 3 - 

 

obligations arising in connection with your employment with the Company, and that you have not
and will not breach any obligations to any prior employer or third party during your employment
with the Company. You also agree that your have not relied on any agreements or representations
with respect to your employment that are not set forth expressly in this letter agreement.

     In the event that you or the Company reasonably believe that Section 409A of the Code will
result in adverse tax consequences to you as a result of this letter agreement, then you and the
Company shall renegotiate this letter agreement in good faith in order to minimize or eliminate
such tax consequences and retain the basic economics of this letter agreement to the greatest
extent possible.

     The Company agrees that you may continue to serve on the Board of Directors of Affinium
Pharmaceuticals, Inc. provided (i) you continue to comply with your obligations under your
invention and non-disclosure and non-competition and non-solicitation agreements with the Company
and (ii) such service does not create a conflict of interest for you as an officer or director of
the Company.

     For purposes of this letter agreement, the following terms shall have the following meanings:

     “Cause” shall mean: (i) a good faith finding by the Board of Directors of the Company of (A)
your repeated failure after written notice to perform your reasonably assigned duties for the
Company and a reasonable opportunity to cure the alleged failure; (B) that you have engaged in
dishonesty, gross negligence or willful misconduct, which dishonesty, gross negligence or
misconduct has had a material adverse effect on the Company; (ii) your conviction of, or the entry
of a pleading of guilty or nolo contendere by you to, any crime involving moral turpitude or any
felony; or (iii) a breach by you of any material provision of any invention and non-disclosure
agreement or non-competition and non-solicitation agreement with the Company, which breach (to the
extent such breach is curable) is not cured within ten days written notice thereof.

     “Good Reason” shall mean: (i) mutual written agreement by you and the Board of Directors of
the Company that Good Reason exists; (ii) the relocation of the Company’s offices in Waltham,
Massachusetts such that your daily commute is increased by at least 60 miles without your written
consent; (iii) reduction of your annual base salary without prior consent (other than in connection
with, and substantially proportionate to, reductions by the Company of the annual base salary of
more than 75% of its executive employees); (iv) any material breach by the Company or any successor
thereto of any agreement to which you and the Company are parties, including, without limitation,
this letter agreement, which breach is not cured within ten days of written notice thereof; or (v)
your demotion to a position with responsibilities substantially less than your current position.

     “Disability” shall mean your inability, due to a physical or mental disability, for a period
of 120 days, whether or not consecutive, during any 360-day period, to perform the services
contemplated under this letter agreement, with or without reasonable

1365 Main Street
• Waltham, MA 02451 • T: (781) 891-3745
• F: (781) 891-3796 •
www.compundtherapeutics. com

 - 4 - 

 

accommodation, as that term is defined under state or federal law. A determination of
disability shall be made by a physician reasonably satisfactory to the Company and you.

     “Change of Control” shall mean the sale of all or substantially all of the capital stock
(other than the sale of capital stock to one or more venture capitalists or other institutional
investors pursuant to an equity financing (including a debt financing that is convertible into
equity)) of the Company, or assets or business of the Company, by merger, consolidation, sale of
assets or otherwise (other than a transaction in which all or substantially all of the individuals
and entities who were beneficial owners of the Common Stock immediately prior to such transaction
beneficially own, directly or indirectly, more than 50% of the outstanding securities entitled to
vote generally in the election of directors of the resulting, surviving or acquiring corporation in
such transaction).

     We have agreed that you will begin work as soon as possible, but in any case no later than May
15, 2005. As I have told you, we are extremely pleased that you have decided to accept the offer
and are looking forward to working with you. If the terms described in this letter agreement
accurately reflect our understanding regarding your employment, please indicate your agreement by
signing in the space below and returning this letter agreement to me no later than April 29, 2005.

Sincerely,

	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ John Mendlein
	 	 	 	May 15, 2005	 	 
	 

	 	 
	 	 	 	 	 	 
	 

	 	Name:      John D. Mendlein
	 	 	 	Date	 	 
	 
	 	 	 	 	 	 	 	 
	Accepted	 	and Agreed:	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	/s/ Frank Lee	 	 	 	May 12, 2005	 	 
	 	 	 	 	 	 	 
	Frank D. Lee, Ph.D.	 	 	 	Date	 	 
	President and CEO	 	 	 	 	 	 

1365 Main Street
• Waltham, MA 02451 • T: (781) 891-3745
• F: (781) 891-3796 •
www.compundtherapeutics. com

 - 5 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00128-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00128-of-00352.parquet"}]]